Top

Published in:

01-10-2011 | PRECLINICAL STUDIES

Intercalative pyrimido[4′,5′:4,5]thieno(2,3-b)quinolines induce apoptosis in leukemic cells: a comparative study of methoxy and morpholino substitution

Authors: M. S. Shahabuddin, Mridula Nambiar, Gopal M. Advirao, Sathees C. Raghavan

Published in: Investigational New Drugs | Issue 5/2011

Summary

DNA intercalating molecules are promising anticancer agents. Polycyclic aromatic molecules such as ellipticine intercalate into double-stranded DNA and affect major physiological functions. In the present study, we have characterized two molecules with the same chemical backbone but different side chains, namely 8-methoxy pyrimido[4′,5′:4,5]thieno (2,3-b)quinoline-4(3H)-one (MPTQ) and 4-morpholino pyrimido[4′,5′:4,5]thieno(2,3-b)quinoline (morpho-PTQ) at the 8th and 4th position, respectively. Although both MPTQ and morpho-PTQ show similar biophysical properties with high DNA affinity, here we show that they differ in their biological activities. We find that MPTQ is many fold more potent than morpho-PTQ and is cytotoxic against different leukemic cell lines. IC₅₀ value of methoxy PTQ was estimated between 2–15 µM among the leukemic cells studied, while it was more than 200 µM when morpho-PTQ was used. Cell cycle analysis shows an increase in sub-G1 phase, without any particular cell cycle arrest. Annexin V staining in conjunction with comet assay and DNA fragmentation suggest that MPTQ induces cytotoxicity by activating apoptosis. Thus the observed low IC₅₀ value of MPTQ makes it a promising cancer chemotherapeutic agent.

Mazzitelli CL et al (2007) Screening of threading bis-intercalators binding to duplex DNA by electrospray ionization tandem mass spectrometry. J Am Soc Mass Spectrom 18(2):311–321PubMedCrossRef

Portugal J (2009) Evaluation of molecular descriptors for antitumor drugs with respect to noncovalent binding to DNA and antiproliferative activity. BMC Pharmacol 9:11PubMedCrossRef

Minotti G et al (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185–229PubMedCrossRef

Strekowski L, Wilson B (2007) Noncovalent interactions with DNA: an overview. Mutat Res 623(1–2):3–13PubMed

Chaires JB (2006) A thermodynamic signature for drug-DNA binding mode. Arch Biochem Biophys 453(1):26–31PubMedCrossRef

Wheate NJ et al (2007) DNA intercalators in cancer therapy: organic and inorganic drugs and their spectroscopic tools of analysis. Mini Rev Med Chem 7(6):627–648PubMedCrossRef

Garbett NC, Chaires JB (2008) Binding: a polemic and rough guide. Methods Cell Biol 84:3–23PubMed

Takeuchi Y et al (1997) Synthesis and antitumor activity of fused quinoline derivative. IV. Novel 11-aminoindolo(2, 3-b)quinolines. Chem Pharm Bull (Tokyo) 45:406–411

Monnot M et al (1991) DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem 266(3):1820–1829PubMed

10.

Tilak Raj T, Ambeker SY (1988) Synthesis of pyrimido[4Ι, 5Ι:4, 5]thieno(2, 3-b)quinoline-4(3H)-ones. J Chem Res 50:537–551

11.

Nandeeshaiah SK, Ambeker SY (1994) Synthesis of 2-aryl–1, 2, 3, 4-tetrahydropyrido [2Ι, 3Ι:4, 5] thieno[2, 3-b]quinolin-4-ones. Indian J Chem 33:375–379CrossRef

12.

Gopal M, Shenoy S, Doddamani LS (2003) Antitumour activity of 4-amino and 8-methly-4-(3-diethyl aminopropylamino)pyrimido[4′, 5′:4, 5]thieno(2, 3-b)quinoline. J Photochem Photobiol B 72:69–78PubMedCrossRef

13.

Gopal M, Shahabuddin MS, Inamdar SR (2002) Interaction between 8-methoxypyrimido [4Ι,5Ι:4,5]thieno(2,3-b)quinoline-4(3H)-one antitumour drug and deoxyribo nucleic acid. Proc Indian Acad Sci (Chem Sci) 114:687–696CrossRef

14.

Shahabuddin MS, Gopal M, Raghavan SC (2009) Intercalating, cytotoxic, antitumour activity of 8-chloro and 4-morpholinopyrimido [4′, 5′:4, 5]thieno(2, 3-b)quinolines. J Photochem Photobiol B 94(1):13–19PubMedCrossRef

15.

Shahabuddin MS, Gopal M, Raghavan SC (2007) Intercalating and Antitumour Activity of 4- Oxopyrimido[4′, 5′:4, 5]thieno(2, 3-b)quinoline-4(3H)-one. J Cancer Mol 3(5):139–146

16.

Gopal M, Veeranna S (2005) 4-Anilinopyrimido[4′, 5′:4, 5]selenolo(2, 3-b)quinoline and 4-piperazino pyrimido[4′, 5′:4, 5]selenolo(2, 3-b)quinoline: new DNA intercalating chromophores with antiproliferative activity. J Photochem Photobiol B 81(3):181–189PubMedCrossRef

17.

Shahabuddin MS et al (2009) A novel DNA intercalator, butylamino-pyrimido[4′,5′:4,5]selenolo(2,3-b)quinoline, induces cell cycle arrest and apoptosis in leukemic cells. Invest New Drugs

18.

Shahabuddin MS et al (2010) A novel structural derivative of natural alkaloid ellipticine, MDPSQ, induces necrosis in leukemic cells. Invest New Drugs

19.

Chiruvella KK et al (2008) Methyl angolensate, a natural tetranortriterpenoid induces intrinsic apoptotic pathway in leukemic cells. FEBS Lett 582(29):4066–4076PubMedCrossRef

20.

Freimoser FM et al (1999) The MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay is a fast and reliable method for colorimetric determination of fungal cell densities. Appl Environ Microbiol 65(8):3727–3729PubMed

21.

Kavitha CV et al (2009) Novel derivatives of spirohydantoin induce growth inhibition followed by apoptosis in leukemia cells. Biochem Pharmacol 77(3):348–363PubMedCrossRef

22.

Gowda NR et al (2009) Synthesis and biological evaluation of novel 1-(4-methoxyphenethyl)-1H-benzimidazole-5-carboxylic acid derivatives and their precursors as antileukemic agents. Bioorg Med Chem Lett 19(16):4594–4600PubMedCrossRef

23.

Singh NP et al (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175(1):184–191PubMedCrossRef

24.

Ioannou YA, Chen FW (1996) Quantitation of DNA fragmentation in apoptosis. Nucleic Acids Res 24(5):992–993PubMedCrossRef

25.

Chiruvella KK, Raghavan SC (2010) A natural compound, methyl angolensate, induces mitochondrial pathway of apoptosis in Daudi cells. Invest New Drugs

26.

Hurley LH (2002) DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2:188–200PubMedCrossRef

27.

Dervan PB (2001) Molecular recognition of DNA by small molecules. Bioorg Med Chem 9:2215–2235PubMedCrossRef

28.

Tilak Raj T, Ambekar SY (1988) Synthesis of 4-amino pyrimido [4′, 5′:4, 5]thieno (2, 3-b) quinoline-4(3H)-ones. J Chem Res (S) 50:537–551

29.

Nandeeshaiah SK, Ambekar SY (1998) Synthesis, Dimroth rearrangment and blood platelet disaggregation property of pyrimido[4׀, 5׀:4, 5]selenolo(2, 3-b)quinolines: a new class of condensed quinoline. Indian J Chem 37:995–1000

30.

Lee EJ et al (2004) Induction of G2/M cell cycle arrest and apoptosis by a benz[f]indole-4, 9-dione analog in cultured human lung (A549) cancer cells. Bioorg Med Chem Lett 14(20):5175–5178PubMedCrossRef

31.

Mizutani H et al (2002) Mechanism of apoptosis induced by a new topoisomerase inhibitor through the generation of hydrogen peroxide. J Biol Chem 277(34):30684–30689PubMedCrossRef

Title: Intercalative pyrimido[4′,5′:4,5]thieno(2,3-b)quinolines induce apoptosis in leukemic cells: a comparative study of methoxy and morpholino substitution
Authors: M. S. Shahabuddin
Mridula Nambiar
Gopal M. Advirao
Sathees C. Raghavan
Publication date: 01-10-2011
Publisher: Springer US
Published in: Investigational New Drugs / Issue 5/2011
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-010-9436-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 5/2011

Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα

Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer

Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer